Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
2.660
+0.160 (6.40%)
Nov 25, 2025, 1:50 PM EST - Market open
PACB Stock Forecast
Stock Price Forecast
The 6 analysts that cover PACB stock have a consensus rating of "Buy" and an average price target of $2.00, which forecasts a -24.81% decrease in the stock price over the next year. The lowest target is $1.50 and the highest is $3.00.
Price Target: $2.00 (-24.81%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PACB stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 5 | 5 | 5 | 5 | 5 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Maintains $1.5 → $2 | Hold | Maintains | $1.5 → $2 | -24.81% | Nov 11, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Maintains $1.8 → $2 | Buy | Maintains | $1.8 → $2 | -24.81% | Nov 10, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $1.25 → $1.5 | Hold | Maintains | $1.25 → $1.5 | -43.61% | Aug 11, 2025 |
| Barclays | Barclays | Hold Maintains $2 → $1.5 | Hold | Maintains | $2 → $1.5 | -43.61% | Jun 25, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $2 → $1.25 | Hold | Maintains | $2 → $1.25 | -53.01% | May 15, 2025 |
Financial Forecast
Revenue This Year
163.34M
from 154.01M
Increased by 6.06%
Revenue Next Year
188.09M
from 163.34M
Increased by 15.15%
EPS This Year
-1.65
from -1.13
EPS Next Year
-0.55
from -1.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 170.1M | 211.7M | |||
| Avg | 163.3M | 188.1M | |||
| Low | 154.3M | 168.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.4% | 29.6% | |||
| Avg | 6.1% | 15.2% | |||
| Low | 0.2% | 3.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.59 | -0.49 | |||
| Avg | -1.65 | -0.55 | |||
| Low | -1.90 | -0.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.